

Human Whole Exome Sequencing

1. Sample Requirements

Sample Type	Amount (Qubit®)	Volume	Concentration	Purity (NanoDrop™)
Genomic DNA	≥ 300 ng	\geqslant 15 μ L	≥ 15 ng/μL	OD260/280=1.8-2.0; no degradation, no contamination
cfDNA/ctDNA	≥ 35 ng	≥ 20 μL	≥ 0.5 ng/μL	Fragments should be in multiples of 170 bp, no genomic contamination
Genomic DNA from *FFPE	≥ 400 ng	≥ 20 μL	≥ 20 ng/μL	Fragments should be longer than 1000 bp

^{*}FFPE: Formalin-fixed-paraffin-embedded

2. Sequencing Parameters

Platform	Illumina NovaSeq 6000		
Read length	Paired-end 150 bp		
Recommended sequencing depth	For Mendelian disorder/rare disease: effective sequencing depth above $50 \times (6 \text{ G})$; For tumor sample: effective sequencing depth above $100 \times (12 \text{ G})$		
Data quality	Guaranteed ≥ 85% bases with Q30 or higher		
**Turnaround time	As quick as 14 working days from confirmation of QC report to data release without analysis.		

^{**}Turnaround time varies depending on the project volume.

3. Data Analysis Contents

Standard Analysis

Data quality control: filtering reads containing adapter or with low quality

Alignment with reference, statistics of sequencing depth and coverage

SNP and InDel calling, annotation and statistics

Somatic variant detection (only apply for tumor-normal paired samples) SNP calling, annotation and statistics InDel calling, annotation and statistics CNV calling, annotation and statistics



	Methods		
Advanced analysis	Cancer	Screening for Predisposing Genes (feasible if only normal samples are provided)	
		Mutational Spectrum & Mutational Signature	
	Driver gene analysis	Identification of Known Driver Genes	
		Significantly Mutated Gene & Pathway Analysis	
		Mutation Relation Test of Significantly Mutated Genes	
		Identification of Driver Genes Based on Mutation Clustering Bias	
		Identification of Driver Somatic CNVs	
		Mutation Site Displaying	
	Tumor heterogeneity analysis	Tumor Purity & Ploidy Estimation	
		Intra-tumor Heterogeneity Analysis	
		Tumor Evolution Analysis (One normal and at least 3 tumor samples from the same patient are needed)	
		Tumor Neoantigen Identification	
	Monogenic disease	Candidate Variant Filtration	
		Analysis under dominant / recessive model	
		Linkage Analysis	
		Region of Homozygosity Analysis (ROH)	
	Polygenic disease	Candidate Variant Filtration	
		Analysis under dominant / recessive model	
		Linkage Analysis	
		Region of Homozygosity Analysis (ROH)	
		De novo SNV/InDel Analysis	